CMPX · CIK 0001738021
What Compass Therapeutics, Inc. told the SEC could break it.
Compass Therapeutics' disclosures describe a pre-revenue biotech funding itself toward an uncertain approval. It has never generated product revenue and posted a $66 million net loss in 2025 — and though it held $209 million in cash and investments at year-end, it expects continued losses for years and to keep funding operations through equity or debt. It relies on third-party contract manufacturers for clinical (and eventually commercial) supply of its candidates, and if any are approved, future U.S. economics would face drug-pricing pressure from the IRA and December 2025 CMS proposals (GLOBE and GUARD) that would tie rebates on single-source drugs and biologics to international benchmark prices.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Liquidity & debt
- pre-revenue, ongoing losses, financing dependencemedium
Compass has no product revenue and significant operating losses (net loss of $66M in 2025); though it held $209M in cash/investments at year-end 2025, it expects continued losses for years and to fund operations via equity/debt financings.
“Since our inception, we have not generated any revenue from any product sales or any other sources, and we have incurred significant operating losses. We have not yet commercialized any products and we do not expect to generate revenue from sales of products for several years, if at all.”
SEC filing →As of 2026
Regulatory & policy
- US drug-pricing reform (IRA, MFN GLOBE/GUARD)medium
If its candidates are approved, Compass would face US drug-pricing pressure — IRA reforms plus December 2025 CMS proposals (GLOBE for Medicare Part B, GUARD for Part D) that would tie single-source drug/biologic rebates to international (MFN) benchmark prices.
“On December 19, 2025, CMS released two proposed rules that would incorporate MFN pricing principles into federal reimbursement for prescription drugs. The first proposal, the Global Benchmark for Efficient Drug Pricing Model (“GLOBE”) for Medicare Part B, would require manufacturers of specified single source drugs and sole source biologics to pay incremental rebates based on international benchmark prices”
SEC filing →As of 2026
Supplier concentration
- third-party CMO manufacturingmedium
Compass relies on third parties to produce clinical quantities of its product candidates and expects to rely on third parties for commercial quantities; manufacturer compliance issues or disruptions could delay production and distribution.
“We rely on third parties for the production of clinical quantities of our product candidates and expect to rely in the future on third parties for the production of commercial quantities.”
SEC filing →As of 2026
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch